P. Raeymaekers, V. Timmerman, E. Nelis, D. Jonghe, P. Hoogendijk et al., Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT 1a), Neuromuscular Disorders, vol.1, issue.2, pp.93-100, 1991.
DOI : 10.1016/0960-8966(91)90055-W

J. Lupski, C. Wise, A. Kuwano, and L. Pentao, Gene dosage is a mechanism for Charcot-Marie-Tooth disease type 1A, Nature Genetics, vol.46, issue.1, pp.29-33, 1992.
DOI : 10.1016/0960-8966(91)90055-W

D. Pareyson, V. Scaioli, and M. Laurà, Clinical and electrophysiological aspects of Charcot-Marie-Tooth disease, NeuroMolecular Medicine, vol.8, issue.1-2, pp.3-22, 2006.
DOI : 10.1385/NMM:8:1-2:3

T. Bird, Charcot-Marie-Tooth Neuropathy Type 1, GeneReviews, 2014.

E. Passage, J. Norreel, P. Noack-fraissignes, V. Sanguedolce, J. Pizant et al., Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease, Nature Medicine, vol.10, issue.4, pp.396-401, 2004.
DOI : 10.1038/nm1023

F. Kaya, S. Belin, P. Bourgeois, J. Micaleff, O. Blin et al., Ascorbic acid inhibits PMP22 expression by reducing cAMP levels, Neuromuscular Disorders, vol.17, issue.3, pp.248-53, 2007.
DOI : 10.1016/j.nmd.2006.12.008

C. Verhamme, R. De-haan, M. Vermeulen, F. Baas, M. De-visser et al., Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial, BMC Medicine, vol.16, issue.1, p.70, 2009.
DOI : 10.1016/j.nmd.2006.03.008

J. Burns, R. Ouvrier, E. Yiu, P. Joseph, A. Kornberg et al., Ascorbic acid for Charcot???Marie???Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial, The Lancet Neurology, vol.8, issue.6, pp.537-581, 2009.
DOI : 10.1016/S1474-4422(09)70108-5

C. Toth, Poor tolerability of high dose ascorbic acid in a population of genetically confirmed adult Charcot-Marie-Tooth 1A patients, Acta Neurologica Scandinavica, vol.70, issue.2, pp.134-142, 2009.
DOI : 10.1111/j.1600-0404.2008.01134.x

J. Micallef, S. Attarian, O. Dubourg, P. Gonnaud, J. Hogrel et al., Effect of ascorbic acid in patients with Charcot???Marie???Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial, The Lancet Neurology, vol.8, issue.12, pp.1103-1113, 2009.
DOI : 10.1016/S1474-4422(09)70260-1

D. Pareyson, M. Reilly, A. Schenone, G. Fabrizi, T. Cavallaro et al., Ascorbic acid in Charcot???Marie???Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial, The Lancet Neurology, vol.10, issue.4, pp.320-328, 2011.
DOI : 10.1016/S1474-4422(11)70025-4

R. Lewis, M. Mcdermott, D. Herrmann, A. Hoke, L. Clawson et al., High-Dosage Ascorbic Acid Treatment in Charcot-Marie-Tooth Disease Type 1A, JAMA Neurology, vol.70, issue.8, pp.981-988, 2013.
DOI : 10.1001/jamaneurol.2013.3178

I. Chumakov, A. Milet, N. Cholet, G. Primas, A. Boucard et al., Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy, Orphanet Journal of Rare Diseases, vol.32, issue.1, p.201, 2014.
DOI : 10.1186/s13023-014-0201-x

S. Attarian, J. Vallat, L. Magy, B. Funalot, P. Gonnaud et al., An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A, Orphanet Journal of Rare Diseases, vol.120, issue.3, p.199, 2014.
DOI : 10.1186/s13023-014-0199-0

M. Reilly, M. Shy, F. Muntoni, and D. Pareyson, 168th ENMC International Workshop: Outcome measures and clinical trials in Charcot???Marie???Tooth disease (CMT), Neuromuscular Disorders, vol.20, issue.12, pp.839-885, 2010.
DOI : 10.1016/j.nmd.2010.08.001

M. Shy, J. Blake, K. Krajewski, D. Fuerst, L. M. Hahn et al., Reliability and validity of the CMT neuropathy score as a measure of disability, Neurology, vol.64, issue.7, pp.1209-1223, 2005.
DOI : 10.1212/01.WNL.0000156517.00615.A3

R. Graham and R. Hughes, A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale, Journal of Neurology, Neurosurgery & Psychiatry, vol.77, issue.8, pp.973-979, 2006.
DOI : 10.1136/jnnp.2005.081547

M. Shy, L. Chen, E. Swan, R. Taube, K. Krajewski et al., Neuropathy progression in Charcot-Marie-Tooth disease type 1A, Neurology, vol.70, issue.5, pp.378-83, 2008.
DOI : 10.1212/01.wnl.0000297553.36441.ce

S. Tesfaye, R. Tandan, E. Bastyr, K. Kles, V. Skljarevski et al., Factors That Impact Symptomatic Diabetic Peripheral Neuropathy in Placebo-Administered Patients From Two 1-Year Clinical Trials, Diabetes Care, vol.30, issue.10, pp.2626-2658, 2007.
DOI : 10.2337/dc07-0608

A. Hróbjartsson and P. Gøtzsche, Placebo interventions for all clinical conditions, Cochrane Database Syst Rev, issue.1, p.3974, 2010.

S. Murphy, D. Herrmann, M. Mcdermott, S. Scherer, M. Shy et al., Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease, Journal of the Peripheral Nervous System, vol.9, issue.3, pp.191-199, 2011.
DOI : 10.1111/j.1529-8027.2011.00350.x

R. Sadjadi, M. Reilly, M. Shy, D. Pareyson, L. M. Murphy et al., Psychometrics evaluation of Charcot-Marie-Tooth Neuropathy Score (CMTNSv2) second version, using Rasch analysis, Journal of the Peripheral Nervous System, vol.6, issue.3, pp.192-198, 2014.
DOI : 10.1111/jns.12084

M. Mannil, A. Solari, A. Leha, A. Pelayo-negro, J. Berciano et al., Selected items from the Charcot-Marie-Tooth (CMT) Neuropathy Score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients, Neuromuscular Disorders, vol.24, issue.11, pp.1003-1020, 2014.
DOI : 10.1016/j.nmd.2014.06.431